Live Analyst Rating Changes 23582 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Stanton
JEF

David Stanton

Jefferies
Wall Street Analyst
★★★☆☆
#1500
on 13Foresight · ranked by our own returns
58%
Success Rate
+2.2%
Average Return
19 of 33 calls profitable · -3.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 58% of David Stanton's ratings turned a profit when each position was held for 1 year — averaging +2.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

33 Buy 20 Hold 0 Sell
David's Stock Coverage 17 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:NEU
Neuren Pharmaceuticals Limited
 Aug 05, 2026 BUY Strong Buy
+7.8% avg upside
4 analysts
$29.40
26.07% Upside
 +5.4% ·
AU:MSB
Mesoblast Limited
 Jul 28, 2026 BUY Strong Buy
+24.9% avg upside
1 analyst
$3.00
24.93% Upside
 +9.3% ·
AU:RHC
Ramsay Health Care
 Jul 28, 2026 HOLD Hold
-7.2% avg upside
14 analysts
$39.80
11.42% Downside
 +1.5% ·
AU:CU6
Clarity Pharmaceuticals Ltd.
 Jul 28, 2026 BUY Strong Buy
+150.9% avg upside
2 analysts
$5.60
99.24% Upside
 +28.7% ·
AU:SHL
Sonic Healthcare Limited
 Jul 28, 2026 HOLD Buy
+14.8% avg upside
12 analysts
$23.00
3.11% Upside
 -2.1% ·
AU:IDX
Integral Diagnostics Ltd.
 Jul 28, 2026 BUY Strong Buy
+40.7% avg upside
12 analysts
$3.70
66.69% Upside
 +4.3% ·
AU:MVF
Monash IVF Group Ltd
 Jul 28, 2026 BUY Strong Buy
+41.1% avg upside
7 analysts
$0.83
19.46% Upside
 +0.0% ·
AU:COH
Cochlear
Jul 28, 2026 HOLD Hold
+34.8% avg upside
15 analysts
$128.40
2.46% Downside
 +1.9% ·
AU:CUV
Clinuvel Pharmaceuticals
Jul 28, 2026 BUY Strong Buy
+214.9% avg upside
3 analysts
$40.80
329.54% Upside
 -1.6% ·
AU:CSL
CSL
 Jul 28, 2026 HOLD Strong Buy
+37.4% avg upside
16 analysts
$119.00
14.01% Downside
 +3.2% ·
AU:HLS
Healius Limited
 Jul 28, 2026 HOLD Sell
+100.1% avg upside
10 analysts
$0.38
9.44% Downside
 +12.0% ·
AU:PME
Pro Medicus Limited
 Jul 28, 2026 HOLD Buy
+41.7% avg upside
9 analysts
$195.80
7.77% Upside
 +7.4% ·
AU:TLX
Telix Pharmaceuticals
 Jul 21, 2026 BUY Strong Buy
+50.7% avg upside
14 analysts
$29.00
71.81% Upside
 +8.9% ·
AU:SIG
Sigma Healthcare Ltd
 May 05, 2026 BUY Strong Buy
+113.1% avg upside
10 analysts
$3.30
11.43% Upside
 +2.1% ·
AU:IMM
Immutep Ltd
 Mar 13, 2026 HOLD Buy
+1167.4% avg upside
4 analysts
$0.04
21.52% Downside
 -21.3% ·
MESO
Mesoblast
 Dec 06, 2022 HOLD Strong Buy
+46.6% avg upside
14 analysts
 — -67.9% ·
SKHHY
Sonic Healthcare
 Apr 08, 2021 HOLD Buy
5 analysts
 — -1.1% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Stanton — Frequently Asked Questions
How accurate are David Stanton's stock ratings?
Based on the calls 13Foresight could measure, about 58% of David's ratings were profitable over a one-year hold, with an average return of +2.2% per rating, or -3.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Stanton is currently ranked #1500 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on AU:NEU, AU:MSB, AU:RHC, AU:CU6, AU:SHL, AU:IDX, AU:MVF, AU:COH, AU:CUV, AU:CSL, AU:HLS, AU:PME and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.